Europe — EMA
Panzyga (Human Normal Immunoglobulin)
GNH USA supplies Panzyga (Human normal immunoglobulin), a Immunoglobulin (IVIG) for primary immunodeficiency, secondary immunodeficiency and ITP.
Request sourcing
What is Human Normal Immunoglobulin?
Human normal immunoglobulin, the active ingredient in Panzyga, is an Immunoglobulin (IVIG) presented as a solution for injection for intravenous use. It provides passive immunity and is used in patients with primary or secondary immunodeficiency diseases and immune thrombocytopenic purpura. GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.
GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.
What is Human Normal Immunoglobulin used for?
Panzyga is used in immunology to replace deficient antibodies and modulate immune responses in several conditions.
- Primary immunodeficiency diseases: helps restore normal IgG levels and reduces infection frequency. - Secondary immunodeficiency: supports immune function when antibody production is compromised. - Immune thrombocytopenic purpura: contributes to platelet count stabilization by immune modulation.
What are the side effects of Human Normal Immunoglobulin?
Adverse reactions to Panzyga can vary from mild to severe and are monitored during and after infusion.
Common Side Effects: - Headache - Fever - Chills - Nausea - Fatigue - Myalgia
Serious or Rare Side Effects: - Anaphylaxis - Thromboembolic events - Acute renal failure - Hemolytic anemia - Severe aseptic meningitis - Transfusion‑related acute lung injury (TRALI)
What precautions apply to Human Normal Immunoglobulin?
Before initiating therapy with Panzyga, clinicians should consider several safety aspects.
- Renal function assessment: evaluate baseline kidney function and monitor during treatment. - Thrombotic risk evaluation: assess patient history for clotting disorders. - Infusion rate management: start with a slow rate and adjust based on tolerance. - Pre‑medication: consider antihistamines or analgesics to reduce infusion reactions. - Contraindications: avoid use in patients with known severe IgA deficiency with anti‑IgA antibodies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Human Normal Immunoglobulin interact with?
Panzyga may interact with other medicines, requiring attention to dosing and monitoring.
Major Interactions (Avoid): - Live vaccines: concurrent administration can reduce vaccine efficacy and increase risk.
Moderate Interactions (Monitor Closely): - Corticosteroids: may enhance immunosuppressive effects, requiring dose adjustments. - Anticoagulants: increased risk of bleeding; monitor coagulation parameters. - Diuretics: may affect renal handling of fluids; watch for volume overload. - ACE inhibitors: potential for additive renal effects; monitor kidney function. - Rituximab: combined immunosuppression may increase infection risk.
